Aim: The aim of this study is to assess the impact of Olmesartan compared to Cilnidipine on urinary microalbumin levels in patients diagnosed with hypertension and type II diabetes mellitus. Materials and Methods: This study included individuals who were recently diagnosed with type II Diabetes Mellitus and also had hypertension, with a blood pressure equal to or greater than 140/90 mmHg. Additionally, patients with microalbuminuria were also included in the study. A total of 100 patients were allocated into two groups, with each group consisting of 50 patients. Group I received Tab Olmesartan 20mg and Group II received Tab Cilnidipine 10mg. Results: In Group I, the average reduction in microalbuminuria was found to be 17.43±2.32 mg, while in Group II, the average reduction was 23.03±2.34 mg. The findings indicate a significant decrease in systolic blood pressure in both groups following a 6-month therapy period. A statistically significant decrease in diastolic blood pressure in both groups after a 6-month therapy period, as determined through the application of a paired t-test. Conclusion: Both cilnidipine and Olmesartan have been found to be effective and well-tolerated in individuals diagnosed with essential hypertension and type 2 diabetes mellitus.